GlassScriptPhysician profile
Amy B Matorin
NPI 1811195720
$7,871.54
in general payments reported to CMS, 2019-2025
32 companies · $1,509 in 2025
The $1,509 reported for 2025 was more than what 89% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,407 · 2022: $1,479 · 2023: $1,466 · 2024: $2,011 · 2025: $1,509.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,413 · Consulting Fee: $375 · Education: $133 · Travel and Lodging: $64.20.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,413.24 |
| Consulting Fee | $375.00 |
| Education | $133.39 |
| Travel and Lodging | $64.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,654.25 | 2021-2025 | |
| Janssen Biotech, INC. | $1,174.20 | 2021-2025 | Tremfya |
| Sun Pharmaceutical Industries INC. | $595.80 | 2021-2025 | Ilumya, Blu-U |
| Novartis Pharmaceuticals Corporation | $493.71 | 2021-2025 | |
| Lilly USA, LLC | $447.96 | 2021-2025 | Taltz, Olumiant, Ebglyss |
| Regeneron Healthcare Solutions, INC. | $360.72 | 2021-2024 | Dupixent, Libtayo |
| Galderma Laboratories, L.P. | $358.30 | 2021-2025 | Aklief, Nemluvio, Dysport |
| E.R. Squibb & Sons, L.L.C. | $312.09 | 2022-2025 | Sotyktu |
| Amgen INC. | $303.71 | 2022-2024 | Otezla |
| Leo Pharma INC. | $296.96 | 2021-2025 | Adbry |
| Genzyme Corporation | $269.93 | 2021-2025 | |
| Incyte Corporation | $252.13 | 2023-2025 | Opzelura |
| Pfizer INC. | $223.73 | 2022-2025 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $158.62 | 2021-2025 | Cabtreo, Arazlo |
| Arcutis Biotherapeutics, INC. | $123.39 | 2023-2025 | Zoryve |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Scientific Affairs, LLC | $111.08 | 2022 | |
| Merz North America, INC. | $106.41 | 2023 | Xeomin |
| Ucb, INC. | $100.02 | 2021-2024 | Bimzelx |
| Dermavant Sciences, INC. | $65.67 | 2024 | Vtama |
| Biofrontera INC. | $65.59 | 2021 | |
| Sanofi-Aventis U.S. LLC | $64.99 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $59.68 | 2024-2025 | Spevigo |
| Epi Health, LLC | $58.17 | 2021 | |
| Botanix Sb INC | $47.75 | 2025 | Sofdra |
| Vyne Pharmaceuticals INC. | $40.50 | 2021 | |
| Mayne Pharma Commercial LLC | $24.83 | 2022-2023 | |
| Lnhc, INC | $24.76 | 2025 | Zelsuvmi |
| Blueprint Medicines Corporation | $24.11 | 2025 | Ayvakit |
| Genentech USA, INC. | $14.89 | 2021 | |
| Stemline Therapeutics INC. | $14.42 | 2021 | |
| Merck Sharp & Dohme LLC | $13.91 | 2021 | |
| Organon LLC | $9.26 | 2025 | Vtama |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Matorin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.